When two innovation-heavy players join forces, the stakes rise fast. Biogen and Dayra Therapeutics have announced a new research collaboration that aims to do exactly that—push immunology treatment into a new era with oral macrocyclic peptides.
Immunology drugs are powerful. But most come as injectables. Macrocyclic peptides may change that.
These compounds offer biologic-like efficacy but in an oral format. That means potentially easier dosing, more patient comfort, and fewer barriers to long-term treatment.
Both companies will work together to:
Dayra brings its cutting-edge discovery platform. Biogen brings deep immunology expertise and a global development engine.
For Biogen, this partnership strengthens its early-stage immunology pipeline. It also adds a clinically validated modality to its growing toolkit.
Biogen’s head of research, Jane Grogan, summed it up well:
“We are adding another potential best-in-class approach to target multiple high-value immunological conditions.”
For Dayra, this collaboration is a validation moment. The company believes its macrocyclic peptide platform can unlock next-generation oral treatments.
Acting CEO Rami Hannoush highlighted the milestone:
“We look forward to working with Biogen to unlock the potential of this innovative class of medicines.”
This collaboration won’t reshape immunology overnight. But it signals something important: A move toward oral, highly targeted treatments that could give biologics a real challenge.